<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281342</url>
  </required_header>
  <id_info>
    <org_study_id>ID-080-108</org_study_id>
    <secondary_id>2019-003617-34</secondary_id>
    <nct_id>NCT04281342</nct_id>
  </id_info>
  <brief_title>To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women</brief_title>
  <official_title>Prospective, Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, 4-way Crossover Phase 1 Study to Assess the Effect of Multiple Therapeutic and Supratherapeutic Doses of Aprocitentan on the QT Interval Duration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that multiple-dose administration of oral therapeutic and supratherapeutic&#xD;
      doses of aprocitentan do not have a clinically relevant effect on the QT interval.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Actual">September 3, 2021</completion_date>
  <primary_completion_date type="Actual">August 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each subject will be randomized immediately prior to first study treatment administration on Day 1 Period 1 to one of 12 treatment sequences following a 3 × 4 × 4 Williams square design. Moxifloxacin will be open-label on Day 10 in one period.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo-controlled.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected change from baseline in QT interval corrected with Fridericia's formula (ΔΔQTcF)</measure>
    <time_frame>Multiple predefined time points related to study treatment administration on Day 1 and Day 10 to 11 of each treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aprocitentan trough plasma concentrations (Ctrough)</measure>
    <time_frame>Day 2 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aprocitentan plasma Cmax, first dose</measure>
    <time_frame>Pre-defined times on the first dosing day (Day 1) up to 15 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aprocitentan plasma Cmax, steady state</measure>
    <time_frame>Pre-defined times on the last dosing day (Day 10) up to 15 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUCτ) during a dosage interval (τ) of aprocitentan</measure>
    <time_frame>Day 1 to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aprocitentan attainment of steady-state conditions</measure>
    <time_frame>Day 1 to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index between the first and the last dosing day of aprocitentan</measure>
    <time_frame>Day 1; Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Aprocitentan 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprocitentan 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supratherapeutic dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprocitentan 25 mg</intervention_name>
    <description>Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.</description>
    <arm_group_label>Aprocitentan 25 mg</arm_group_label>
    <other_name>ACT-132577</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprocitentan 100 mg</intervention_name>
    <description>Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.</description>
    <arm_group_label>Aprocitentan 100 mg</arm_group_label>
    <other_name>ACT-132577</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moxifloxacin control to establish assay sensitivity</intervention_name>
    <description>Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in a language understandable to the subject prior to any&#xD;
             study-mandated procedure.&#xD;
&#xD;
          -  Ability to communicate well with the investigator, in a language understandable to the&#xD;
             subject, and to understand and comply with the requirements of the study.&#xD;
&#xD;
          -  No clinically significant findings on the physical examination at screening.&#xD;
&#xD;
          -  Body mass index 18.0 to 30.0 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          -  Systolic blood pressure 90-140 mmHg, diastolic blood pressure 50-90 mmHg, and pulse&#xD;
             rate 50-90 bpm (all inclusive), measured on the same arm, after 5 minutes in the&#xD;
             supine position at screening.&#xD;
&#xD;
          -  12-lead safety ECG: QTcF less than 450 ms for male subjects and less than 470 ms for&#xD;
             female subjects, QRS less than 110 ms, PR less than 220 ms, and resting HR greater&#xD;
             than 50 bpm and less than 90 bpm with no clinically relevant abnormalities on 12-lead&#xD;
             ECG after at least 5 min in the supine position at Screening and on Day 1 pre-dose of&#xD;
             Period 1.&#xD;
&#xD;
          -  No clinically relevant findings in clinical laboratory tests (hematology, clinical&#xD;
             chemistry) at screening.&#xD;
&#xD;
          -  Negative results from urine drug screen, urine cotinine test, and breath alcohol tests&#xD;
             at screening and on Day -1 of each period.&#xD;
&#xD;
          -  A woman of childbearing potential (WoCBP) is eligible only if the following applies:&#xD;
&#xD;
               -  Negative serum pregnancy test at screening.&#xD;
&#xD;
               -  Negative urine pregnancy test on Day -1 of each period.&#xD;
&#xD;
               -  Agreement to consistently and correctly use a highly effective method of&#xD;
                  contraception from screening up to at least 30 days after last study treatment&#xD;
                  administration in the last period with in-between periods included.&#xD;
&#xD;
          -  Women of non-childbearing potential (WoNCBP) must meet at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy,&#xD;
&#xD;
               -  Confirmed premature ovarian failure,&#xD;
&#xD;
               -  Post-menopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Previous exposure to aprocitentan or macitentan.&#xD;
&#xD;
          -  Known hypersensitivity to aprocitentan or macitentan or any of the drug product&#xD;
             excipients, or treatments of the same class.&#xD;
&#xD;
          -  Any contraindication or known hypersensitivity to moxifloxacin or any of the drug&#xD;
             product excipients or to other fluoroquinolone antibiotics.&#xD;
&#xD;
          -  Known hypersensitivity or allergy to natural rubber latex.&#xD;
&#xD;
          -  History of major medical or surgical disorders which, in the opinion of the&#xD;
             investigator, are likely to interfere with the absorption, distribution, metabolism,&#xD;
             or excretion of the study treatment (appendectomy and herniotomy allowed,&#xD;
             cholecystectomy not allowed).&#xD;
&#xD;
          -  Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the&#xD;
             evaluation of the study.&#xD;
&#xD;
          -  Previous treatment with any prescribed medications (including vaccines) or&#xD;
             over-the-counter (OTC) medications (including herbal medicines such as St John's Wort,&#xD;
             homeopathic preparations, vitamins, and minerals) within 2 weeks or 5 t½ (whichever is&#xD;
             longer) prior to first study treatment administration with the exception of&#xD;
             contraceptives in female subjects.&#xD;
&#xD;
          -  History or presence of rhythm disorders (e.g., sinoatrial heart block, sick-sinus&#xD;
             syndrome, second- or third-degree atrioventricular block, long QT syndrome,&#xD;
             symptomatic bradycardia, atrial flutter, or atrial fibrillation) or hypokalemia.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

